Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Descripción completa

Detalles Bibliográficos
Autores principales: Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://www.ncbi.nlm.nih.gov/pubmed/26707935
http://dx.doi.org/10.1038/leu.2015.350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://www.ncbi.nlm.nih.gov/pubmed/26707935
http://dx.doi.org/10.1038/leu.2015.350

Ejemplares similares